West pharmaceutical services appoints Robert McMahon as new CFO

EXTON, Pa. - West Pharmaceutical Services, Inc. (NYSE:WST), a healthcare company with a market capitalization of $15.15 billion and an overall "GOOD" financial health rating according to InvestingPro, announced today the appointment of Robert McMahon as Chief Financial Officer, effective August 4, 2025. McMahon will replace Bernard Birkett, who previously announced his retirement plans earlier this year.

Birkett will transition to the role of Senior Advisor to the CEO through the end of 2025 to facilitate a smooth handover.

McMahon joins West from Agilent Technologies Inc., where he has served as CFO since 2018, overseeing finance, audit, treasury, tax, investor relations, IT and procurement functions. His previous experience includes serving as CFO at Hologic, Inc. and spending 20 years at Johnson & Johnson in various financial leadership positions. He has also been an Independent Director at OraSure Technologies, Inc. since 2023.

"I’m excited by the opportunity to join such a well-positioned company with a talented team dedicated to improving patient health," McMahon said in the press release.

West Pharmaceutical Services specializes in injectable drug administration solutions and services. The company operates 50 sites globally, including 25 manufacturing facilities, and employs over 10,000 team members. In fiscal year 2024, West generated $2.89 billion in net sales.

The information in this article is based on a company press release statement.

In other recent news, West Pharmaceutical Services Inc. reported strong financial results for Q1 2025, surpassing earnings expectations with an EPS of $1.45, compared to the forecasted $1.23. The company’s revenue reached $698 million, exceeding the anticipated $684.94 million. Despite the positive earnings results, the company’s stock experienced a decline in pre-market trading. West Pharmaceutical anticipates continued growth in high-value products and has forecasted full-year 2025 net sales between $2.945 billion and $2.975 billion. Additionally, the company announced outcomes from its 2025 Annual Meeting of Shareholders, where all proposed measures, including executive compensation and amendments to the Articles of Incorporation, were approved. KeyBanc reiterated an Overweight rating for West Pharmaceutical, citing significant growth opportunities in the GLP-1 market, which is expected to expand rapidly in the coming years. Recent capacity investments by major pharmaceutical companies are expected to benefit component suppliers like West Pharmaceutical, indicating strong industry confidence in sustained GLP-1 demand.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.